Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease

Digestive and Liver Disease

Volumn 48, Issue 2, 2016, Pages 138-143

  Guiotto, Cristina ^a   Daperno, Marco ^a   Frigerio, Francesco ^a   Vizzini, Margherita ^a   Cerruti, Roberta ^a   Ercole, Elena ^a   Cosimato, Maurizio ^a   Lavagna, Alessandro ^a   Germano, Laura ^a   Migliardi, Marco ^a   Rocca, Rodolfo ^a  

^a MAURIZIANO HOSPITAL   (Italy)

Author keywords

Inflammatory bowel disease; Infliximab; Therapeutic drug monitoring

Indexed keywords

DRUG ANTIBODY; INFLIXIMAB; ANTIBODY; GASTROINTESTINAL AGENT;

ADVERSE OUTCOME; ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DIAGNOSTIC KIT; DRUG MONITORING; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; BLOOD; CROSS-SECTIONAL STUDY; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; PROSPECTIVE STUDY; REPRODUCIBILITY; TREATMENT OUTCOME;

ANTIBODIES; CROSS-SECTIONAL STUDIES; DRUG MONITORING; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84957848250     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.10.023     Document Type: Article

References (37)

1. Dignass A., Lindsay J.O., Sturm A., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: Current management. Journal of Crohn's and Colitis 2012, 6:991-1030.
2. Dignass A., Van Assche G., Lindsay J.O., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. Journal of Crohn's and Colitis 2010, 4:28-62.
3. Orlando A., Armuzzi A., Papi C., et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Digestive and Liver Disease 2011, 43:1-20.
4. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. New England Journal of Medicine 2003, 348:601-608.
5. Farrell R.J., Alsahli M., Jeen Y.T., et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003, 124:917-924.
6. Seow C.H., Newman A., Irwin S.P., et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010, 59:49-54.
7. Yanai H., Lichtenstein L., Assa A., et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clinical Gastroenterology and Hepatology 2015, 13. 522-30.e2.
8. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. Journal of American Medical Association 2011, 305:1460-1468.
9. Zitomersky N.L., Atkinson B.J., Fournier K., et al. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD. Inflammatory Bowel Diseases 2015, 21:307-314.
10. Nanda K.S., Cheifetz A.S., Moss A.C. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. American Journal of Gastroenterology 2013, 108:40-47. quiz 8.
11. Pariente B., Pineton de Chambrun G., Krzysiek R., et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 2012, 18:1199-1206.
12. Ben-Horin S., Waterman M., Kopylov U., et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clinical Gastroenterology and Hepatology 2013, 11:444-447.
13. Sandborn W.J. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology 2003, 124:1140-1145.
14. Steenholdt C., Bendtzen K., Brynskov J., et al. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. American Journal of Gastroenterology 2014, 109:1055-1064.
15. Ungar B., Chowers Y., Yavzori M., et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014, 63:1258-1264.
16. Van Assche G., Vermeire S., Rutgeerts P. Management of loss of response to anti-TNF drugs: change the dose or change the drug?. Journal of Crohn's and Colitis 2008, 2:348-351.
17. Vermeire S., Noman M., Van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
18. Baert F., Drobne D., Gils A., et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clinical Gastroenterology and Hepatology 2014, 12. 1474-81.e2; quiz e91.
19. Cornillie F., Hanauer S.B., Diamond R.H., et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014, 63:1721-1727.
20. Drobne D., Bossuyt P., Breynaert C., et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease. Clinical Gastroenterology and Hepatology 2015, 13. 514-21.e4.
21. Karmiris K., Paintaud G., Noman M., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
22. Vande Casteele N., Khanna R., Levesque B.G., et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut 2014.
23. Rutgeerts P., Vermeire S., Van Assche G. Predicting the response to infliximab from trough serum levels. Gut 2010, 59:7-8.
24. Altman D.G., Bland J.M. Comparison of methods of measuring blood pressure. Journal of Epidemiology and Community Health 1986, 40:274-277.
25. Altman D.G., Bland J.M. Generalisation and extrapolation. British Medical Journal 1998, 317:409-410.
26. Passing H., Bablok A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part I. Journal of Clinical Chemistry and Clinical Biochemistry 1983, 21:709-720.
27. Schnitzler F., Fidder H., Ferrante M., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
28. Vande Casteele N., Ferrante M., Van Assche G., et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015.
29. Vande Casteele N., Buurman D.J., Sturkenboom M.G., et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Alimentary Pharmacology and Therapeutics 2012, 36:765-771.
30. Marits P., Landucci L., Sundin U., et al. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment. Journal of Crohn's and Colitis 2014, 8:881-889.
31. Corstjens P.L., Fidder H.H., Wiesmeijer K.C., et al. A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study. Analytical and Bioanalytical Chemistry 2013, 405:7367-7375.
32. Wolbink G.J., Voskuyl A.E., Lems W.F., et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2005, 64:704-707.
33. Gisbert J.P., Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. American Journal of Gastroenterology 2009, 104:760-767.
34. Ben-Horin S., Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Alimentary Pharmacology and Therapeutics 2011, 33:987-995.
35. Billioud V., Sandborn W.J., Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. American Journal of Gastroenterology 2011, 106:674-684.
36. Turner D., Lev-Tzion R. Understanding infliximab in Crohn's disease: the long-term outcomes. Digestive Diseases and Sciences 2013, 58:604-607.
37. Paul S., Moreau A.C., Del Tedesco E., et al. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflammatory Bowel Diseases 2014, 20:1288-1295.